Random-bred mice were immunized with a nonliving antigen prepared from mixed-blood forms of Plasmodium berghei, strain NYU-2, in combination with Corynebacterium parvum and/or living BCG. A high proportion of intravenously immunized mice survived virulent challenge, but subcutaneous vaccination was less effective. Vaccinated mice developed a patent infection after challenge similar to that observed in normal controls. However, between days 12 to 20 postchallenge, infections in some vaccinated mice became subpatent, whereas infections in all normal controls progressed until death. The incidence of recrudescent infection was low and, eventually, a state of sterile immunity was established. The capacity of vaccinated mice to withstand P. berghei challenge was sustained at a fairly stable level for the 6-month period of observation. Mice that had survived a primary infection with P. berghei almost completely suppressed a second and larger challenge with the same organism.
It has been shown that nonreplicating plasmodia (14-16), dead parasites, or parasite products (2, 5, 6, 17) may serve as vaccines effective against blood stage infections. Recently, we have shown that protection against Plasmodium berghei in mice is generated in response to immunization with formalized mixed-blood parasites (J. R. Murphy and M. J. Lefford, Am. J. Trop. Med. Hyg., in press). Although this vaccine was moderately effective when administered alone, better protection was obtained when the antigen was given in combination with immunopotentiating agents such as Corynebacterium parvum and living BCG.
In that study, the effectiveness of vaccination was evaluated solely in terms of survival after lethal P. berghei challenge. In the present study, the course of primary and secondary infections with P. berghei has been monitored in terms of mortality and parasitemia; the occurrence of recrudescent and sterile infection has been investigated; and the duration of acquired immunity has been determined. It is reported here that vaccination of ICR mice with an antigen prepared from killed-blood parasites engenders protective immunity of long duration. Further, it is shown that although vaccinated mice can control P. berghei infection, eradication of the parasite takes 7 to 13 weeks, during which recurrent parasitemia is apt to occur. MATERIALS 
RESULTS

Duration of vaccine-induced immunity.
Batches of 120 mice were vaccinated either i.v. or s.c., or set aside as age-matched controls. At intervals thereafter, 10 mice of each group were challenged with P. berghei, parasitemia was measured every 4 days for 40 days, and the numbers of survivors were recorded on day 42 after infection.
The survival data will be considered first ( Fig.  1 ). In the experiment as a whole, all the control mice died, whereas 103 (86%) of the i.v. The patterns of parasitemia during the course of this experiment are shown in Fig. 2 and 3 . There are certain consistent elements that were observed throughout. All infections were subpatent at 4 days, but by day 8 (Fig. 2 and 3) suggests that parasitemia was sustained longer in s.c.-vaccinated mice. This impression might be misleading, due to the larger number of mortally infected mice in the s.c.-vaccinated group.
To clarify this matter, the duration of patent infection in surviving mice was examined (Table  1 ). During the 6-month period of observation, the s.c.-vaccinated mice were found to have significantly longer patent infections than the i.v.-vaccinated mice (P < 0.05). There was little indication that parasitemia was prolonged as the interval between vaccination and challenge increased.
Recrudescence of infection. Vaccinated mice which survived P. berghei challenge were evaluated for recrudescence of infection by examination of blood smears at 2-to 4-day intervals from the termination of patent infection through day 66. All surviving mice were examined through day 42, and a subset of the survivors fromday 42 through 66.
Recrudescences were recorded in 10 lenge were tallied on day 42 after their primary infection and then divided into two groups. One group was observed for recrudescence of infection until day 66 (see above), whereas the other was challenged i.v. for a second time with 106 PRBC of P. berghei. The course of infection in these mice and in concurrently infected normal controls was followed through day 28 (Fig. 4 and  5) . Infections in previously challenged mice differed markedly from infections in normal mice and in mice challenged for the first time after vaccination. None of the rechallenged mice died, and it can be seen that patent infections did not develop in the previously infected groups of mice, regardless of the interval between vaccination and primary infection (1 to 24 weeks).
Sterility of vaccine-associated immunity. Of the vaccinated mice that had received a primary challenge at 20 to 24 weeks after vaccination, there were 21 survivors, 12 of which had been rechallenged. These 21 mice were evaluated for sterility, with respect to P. berghei, on day 90 after their last P. berghei challenge by splenectomy and transfer of spleen homogenates to normal recipients. Nine of the 21 mice died within 24 h of splenectomy, presumably as a result of surgery. It should be realized that the spleens of previously infected mice are enlarged and friable. The remaining 12 splenectomized mice survived for at least 28 days (Table 2) , when the experiment was terminated. No parasites were observed in blood smears prepared from these animals either immediately before splenectomy or at weekly intervals for 4 weeks afterwards. Furthermore, none of the 105 normal mice inoculated with disrupted spleen suspensions died within 4 weeks, yet all of these mice died after subsequent inoculation of 106 P. berghei PRBC. It was concluded that the protection produced by vaccination often resulted in sterile immunity. DISCUSSION These experiments demonstrate that prolonged resistance to otherwise lethal P. berghei challenge is generated by vaccination with Formalin-inactivated blood stage parasites in combination with C. parvum and/or BCG. It should be noted that neither normal RBC membranes, BCG, nor C. parvum generate nonspecific protection to P. berghei in ICR mice (J. R. Murphy It is an undeniable defect of this vaccine that substantial parasitemia follows introduction of the parasite, but this situation is common to a variety of blood stage vaccines. Vaccines prepared either from heat-inactivated parasitized blood (4), or from free parasites which have been enriched for merozoites (11) or from other Formalin-killed parasites (10) have failed to engender an immunity which completely suppressed a challenge infection with P. berghei. A similar result has also been reported for a Formalininactivated P. yoelii vaccine (10) . However, immunity raised with other vaccines has prolonged the prepatent period (1, 2, 8, 15, 17) , suggesting that the challenge inoculum was partly neutralized at the time of inoculation. This type of response was not observed in the present study, in which rapid suppression of P. berghei infection was demonstrated only in vaccinated mice that had survived a primary P. berghei infection and were subjected to a second homologous challenge.
This study reveals that immunity to P. berghei exists as two distant states of immunological reactivity. One is characterized by the capacity to control an infectious challenge at about the time of its introduction; the other is expressed as a heightened immunological responsiveness that enables vaccinated mice to develop a fully effective defense within 12 to 20 days of challenge infection. The former state was observed only in mice which had recovered from a P. berghei infection. The latter was observed in vaccinated mice responding to a primary infection, and resembles a state of immunological memory (3, 9) . It is not known whether the immune response that is engendered by infection eventually changes with time to one which resembles the type of immunity that follows vaccination.
Vaccination with PbF did not furnish the host with an effector mechanism that can control malarial infection ab initio. Rather, the immunized host appeared to generate anamnestically an effector mechanism during the primary infection. Moreover, since the capacity to respond in this way remained unimpaired for at least 6 months, the vaccinated host appeared to possess immunological memory. It is suggested, therefore, that PbF vaccination primed the mouse to P. berghei but did not generate the effector mechanism responsible for clearance of blood infection. In this regard, Trizio 
